Kallikreins are a subgroup of the serine protease enzyme family. Until recently, it was thought that the human kallikrein gene family contained only three members. In the past 3 years, the entire human kallikrein gene locus was discovered and found to contain 15 kallikrein genes. Kallikreins are expressed in many tissues, including steroid hormone-producing or hormone-dependent tissues such as the prostate, breast, ovary, and testis. Most, if not all, kallikreins are regulated by steroid hormones in cancer cell lines. There is strong but circumstantial evidence linking kallikreins and cancer. Prostate-specific antigen (PSA; hK3) and, more recently, human glandular kallikrein (hK2) are widely used tumor markers for prostate cancer. Three other kallikreins, hK6, hK10, and hK11, are emerging new serum biomarkers for ovarian and prostate cancer diagnosis and prognosis. Several other kallikreins are differentially expressed at both the mRNA and protein levels in various endocrine-related malignancies, and they have prognostic value. The coexpression of many kallikreins in the same tissues (healthy and malignant) points to the possible involvement of kallikreins in cascade enzymatic pathways. In addition to their diagnostic/prognostic potential, kallikreins may also emerge as attractive targets for therapeutics.

The Human Kallikrein Gene Locus

The human kallikrein gene locus spans a region of 261 558 bp on chromosome 19q13.4. It is formed of 15 tandemly localized kallikrein genes with no intervention from other genes and is the largest cluster of serine proteases within the human genome. The first report on the expanded human kallikrein multigene locus appeared in 1999 and in an updated form in 2000 (2–4). The same locus was characterized later by others (5, 6). The last member, KLK15, was cloned in 2001 (7). Centromeric to the KLK1 gene lies a nonkallikrein gene, testicular acid phosphatase (ACP1) (8). Telomeric to the last kallikrein gene, KLK14, lies another nonkallikrein gene, Siglec 9, a member of the Siglec multigene family (9, 10). The kallikrein genes in the locus are tightly packaged, with the distances between two adjacent genes ranging from as little as 1.5 kb (KLK1 and KLK15) to 32.5 kb (KLK4 and KLK5). A genomic map of the locus is presented in Fig. 1. No evidence exists for the presence of pseudogenes in this chromosomal region.

We recently constructed the first detailed map of the human kallikrein gene locus with single-base-pair accuracy and defined the direction of transcription of all genes.
It is possible that some genes may still contain unidentified 5′-untranslated exons. The presence of one or more untranslated exons is not uncommon among kallikreins. In addition, many kallikreins have one or more splice variants (7, 11–14). These variants are predicted to encode for truncated proteins. We also examined the kallikrein locus for known repeat elements (15). Approximately 52% of the region is occupied by various repetitive elements (on either strand). Short interspersed nuclear elements, e.g., the ALU and MIR repeats, are the most abundant, followed by the long interspersed nuclear elements. Other repeat elements, such as Tigger2, MER8, and MSRI, were also identified (16).

The locus also contains a unique minisatellite element that is restricted to chromosome 19q13. Ten clusters of this minisatellite are distributed along the kallikrein locus. These clusters are located mainly in the promoters and enhancers of genes, in introns, and in the untranslated regions of the mRNA. PCR analysis of two clusters of these elements indicates that they are polymorphic; thus, they can be useful tools in linkage analysis and DNA fingerprinting. Our preliminary data showed that the distribution of the different alleles of these minisatellites might be associated with malignancy (15).

**Common Structural Features of Kallikreins**

The lengths of all human kallikrein genes range from 4 to 10 kb, with most of the differences attributed to intron lengths. Kallikreins have many common structural features that were considered to establish a universal nomenclature (17). Some features are common among other serine proteases, and others are unique for the kallikrein family. Table 2 summarizes the common structural features of kallikreins.

**Tissue Expression and Hormonal Regulation of Kallikrein Genes**

Many kallikreins are transcribed predominantly in a few tissues, as indicated by Northern blotting. With the more sensitive reverse transcription-PCR (RT-PCR) technique, kallikreins were found to be expressed at lower amounts in several other tissues. The tissue expression of all kallikreins, as assessed by RT-PCR and Northern blot...
analysis, is summarized elsewhere (2, 18, 19). Many kallikreins are expressed in endocrine-related organs. For example, all kallikreins except KLK8 are expressed in the breast, and at least eight kallikreins are expressed in the ovary and ovarian cancer cell lines. Most of the kallikreins are also expressed, to a variable extent, in the prostate and testis.

Several reports have confirmed that many kallikreins are under steroid hormone regulation in cancer cell lines (7, 13, 14, 20–27). An interesting observation is the tissue-specific pattern of regulation of some genes (e.g., the prostate-specific regulation of PSA) and the different patterns of hormonal regulation in different tissues; e.g., KLK4 is up-regulated by androgen in prostate and breast cancer cell lines (24) and by estrogen in endometrial cancer cell lines (25). In addition, KLK12 was found to be up-regulated by androgens and progestins in prostate cancer cell lines and by estrogens and progestins in breast cancer cell lines (28). Details on the hormonal regulation of kallikrein genes have been published elsewhere (18). A noteworthy pattern related to the hormonal regulation is that the centromeric and telomeric groups of kallikreins (KLK1 to -4 and KLK13 to -15) are up-regulated mainly by androgens, whereas the central group is up-regulated mainly by estrogens. It will be interesting to investigate whether there is a common control mechanism regulating groups of kallikreins in parallel. Functional characterization of the promoters of all kallikreins will better define the mechanism of kallikrein gene regulation by steroids.

**Biological Role of Kallikreins**

Only 3 of the 15 kallikreins have been assigned a specific biological function. hK1 exerts its biological activity mainly through the release of lysyl-bradykinin (kallidin) from low-molecular-weight kininogen. However, the diverse expression pattern of hK1 has led to the suggestion that the functional role of this enzyme may be specific to different cell types (29, 30). Apart from its kininogenase activity, tissue kallikrein has been implicated in the processing of growth factors and peptide hormones in light of its presence in pituitary, pancreas, and other tissues (31). As summarized by Bhoola et al. (29), hK1 has been shown to cleave proinsulin, LDL, the precursor of atrial natriuretic factor, prorenin, vasoactive intestinal peptide, procollagenase, and angiotensinogen. Kallikreins in each cell type may possess single or multiple functions, common or unique, but Bhoola et al. (29) suggest that the release of kinin should still be considered the primary effect of hK1.

The physiologic function of hK2 protein has been examined only recently. The study of substrate specificities between hK1 and hK2 reveals important differences, suggesting that the two proteins have different natural substrates, a notion that is supported by the finding of very low kininogenase activity of hK2 compared with hK1 (32, 33). Seminal plasma hK2 cleaves seminogelin I and seminogelin II, but at different cleavage sites and at a lower efficiency than does PSA (34). Because the amount of hK2 in seminal plasma is much lower than PSA (1–5%), the contribution of hK2 to the process of seminal clot liquefaction is expected to be relatively small.

In all biological fluids studied to date, hK3 (PSA) and hK2 were found to coexist, suggesting a possible functional relationship (35–37). Furthermore, a role of hK2 in regulating growth factors, through insulin-like growth factor binding protein-3 (IGFBP-3) proteolysis, has been suggested (38).

Recently, hK2 was found to activate the zymogen or the single-chain form of urokinase-type plasminogen activator (uPA) in vitro (39). Because uPA has been implicated in the promotion of cancer metastasis, hK2 may be part of this pathway in prostate cancer.

Although both hK1 and hK2 have trypsin-like enzymatic activities, hK3 has chymotrypsin-like substrate specificity. PSA is present at very high concentrations in seminal plasma; therefore, most studies focused on its biological activity within this fluid. Lilja (40) has shown that PSA rapidly hydrolyzes both seminogelin I and seminogelin II, as well as fibronectin, causing liquefaction of the seminal plasma clot after ejaculation. Several other potential substrates for PSA have been identified, including IGFBP-3, tumor growth factor-β, basement membrane, parathyroid hormone-related peptide, and plasminogen [reviewed in Ref. (41)]. The physiologic relevance of these findings is still not clear.

hK3 is now known to be found at relatively high concentrations in nipple aspirate fluid, breast cyst fluid,
the milk of lactating women, amniotic fluid, and tumor extracts [reviewed in Ref. (42)]. It is thus very likely that hK3 has extraprostatic biological functions in breast and other tissues and may also play a role during fetal development.

Among all other human kallikreins, some have been connected to physiologic processes and pathologic conditions, but none has been assigned to cleave a specific substrate. Human kallikrein enzymes other than hK1, hK2, and hK3 are not commercially available, and the study of their biological function has not been published. Below, we will attempt to formulate some functional hypotheses for the human kallikreins.

All kallikreins are predicted to be secreted proteases, and it is very likely that their biological function is related to their ability to digest one or more substrates. The diversity of expression in human tissues further suggests that they may act on different substrates in different tissues. Their enzymatic activity may initiate (by activation) or terminate (by inactivation) events mediated by other molecules, including hormones, growth factors, and cytokines. The parallel expression of many kallikreins in the same tissues further suggests that they may participate in cascade reactions similar to those established for the processes of digestion, fibrinolysis, coagulation, and apoptosis. The role of these enzymes in tumor metastasis, as suggested for other proteases (43, 44), should be further investigated.

### Table 3. Kallikrein proteins as cancer biomarkers.

<table>
<thead>
<tr>
<th>Kallikrein</th>
<th>Sample type</th>
<th>Method</th>
<th>Application</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>hK2</td>
<td>Serum and tissue</td>
<td>Immunoassay; immunohistochemistry</td>
<td>Diagnosis, prognosis, and monitoring of prostate and breast cancer</td>
<td>(54)</td>
</tr>
<tr>
<td>hK3 (PSA)</td>
<td>Serum and tissue</td>
<td>Immunoassay; immunohistochemistry</td>
<td>Diagnosis, prognosis, and monitoring of prostate and breast cancer</td>
<td>(42, 54)</td>
</tr>
<tr>
<td>hK6</td>
<td>Serum</td>
<td>Immunoassay</td>
<td>Diagnosis, prognosis, and monitoring of ovarian cancer</td>
<td>(67, 68)</td>
</tr>
<tr>
<td>hK10</td>
<td>Serum</td>
<td>Immunoassay</td>
<td>Prognosis; association with hormone receptors</td>
<td></td>
</tr>
<tr>
<td>hK11</td>
<td>Serum</td>
<td>Immunoassay</td>
<td>Diagnosis and monitoring of ovarian cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ovarian cancer cytosols</td>
<td>Immunoassay</td>
<td>Prognosis; high concentrations associated with poor prognosis</td>
<td>(69)</td>
</tr>
</tbody>
</table>

### Table 4. Kallikrein gene expression (mRNA) and cancer prognosis.

<table>
<thead>
<tr>
<th>Kallikrein</th>
<th>Sample</th>
<th>Method</th>
<th>Application</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>KLK4</td>
<td>Ovarian cancer tissue</td>
<td>RT-PCR</td>
<td>Unfavorable prognostic marker</td>
<td>(63, 65)</td>
</tr>
<tr>
<td>KLK5</td>
<td>Ovarian cancer tissue</td>
<td>RT-PCR</td>
<td>Unfavorable prognostic marker</td>
<td>(64)</td>
</tr>
<tr>
<td></td>
<td>Breast tumor cytosols</td>
<td>RT-PCR</td>
<td>Poor prognosis</td>
<td>(80)</td>
</tr>
<tr>
<td></td>
<td>Healthy and cancerous prostatic tissues</td>
<td>RT-PCR</td>
<td>Unfavorable prognostic marker</td>
<td>(81)</td>
</tr>
<tr>
<td></td>
<td>Healthy and cancerous testicular tissues</td>
<td>RT-PCR</td>
<td>Lower expression in more aggressive tumors</td>
<td>(82)</td>
</tr>
<tr>
<td>KLK6</td>
<td>Ovarian cancer</td>
<td>RT-PCR Northern blot</td>
<td>Overexpression in ovarian cancer</td>
<td>(83)</td>
</tr>
<tr>
<td>KLK7</td>
<td>Ovarian cancer</td>
<td>RT-PCR</td>
<td>Overexpression in ovarian cancer</td>
<td>(62)</td>
</tr>
<tr>
<td>KLK8</td>
<td>Ovarian cancer</td>
<td>RT-PCR</td>
<td>Marker of favorable prognosis</td>
<td>(61)</td>
</tr>
<tr>
<td>KLK9</td>
<td>Ovarian cancer</td>
<td>Northern blot</td>
<td>Higher expression in ovarian cancer</td>
<td>(60)</td>
</tr>
<tr>
<td>KLK10</td>
<td>Breast cancer</td>
<td>In situ hybridization</td>
<td>Marker of favorable prognosis</td>
<td>(66)</td>
</tr>
<tr>
<td>KLK12</td>
<td>Breast cancer</td>
<td>RT-PCR</td>
<td>Down-regulated in breast cancer</td>
<td>(28)</td>
</tr>
<tr>
<td>KLK13</td>
<td>Breast cancer</td>
<td>RT-PCR</td>
<td>Down-regulated in a subset of breast tumors</td>
<td>(14)</td>
</tr>
<tr>
<td>KLK14</td>
<td>Ovarian cancer</td>
<td>RT-PCR</td>
<td>Marker of favorable prognosis</td>
<td>(27)</td>
</tr>
<tr>
<td></td>
<td>Breast cancer</td>
<td>RT-PCR</td>
<td>Down-regulated in breast cancer</td>
<td>(27)</td>
</tr>
<tr>
<td></td>
<td>Healthy and cancerous testicular tissues</td>
<td>RT-PCR</td>
<td>Marker of poor prognosis</td>
<td>(44)</td>
</tr>
<tr>
<td>KLK15</td>
<td>Ovarian cancer</td>
<td>RT-PCR</td>
<td>Marker of favorable prognosis</td>
<td>(44)</td>
</tr>
<tr>
<td></td>
<td>Breast cancer</td>
<td>RT-PCR</td>
<td>Marker of unfavorable prognosis</td>
<td>(44)</td>
</tr>
<tr>
<td></td>
<td>Healthy and cancerous prostatic tissues</td>
<td>RT-PCR</td>
<td>Marker of unfavorable prognosis</td>
<td>(44)</td>
</tr>
</tbody>
</table>
Interactions between serine proteases are common, and substrates of serine proteases are usually other serine proteases that are activated from an inactive precursor (45). The involvement of serine proteases in cascade pathways is well documented. One important example is the blood coagulation cascade. In this enzymatic cascade, the activated form of one factor catalyzes the activation of the next factor. Very small amounts of the initial factors are thus sufficient to trigger the cascade because of the catalytic nature of the process. These numerous steps yield a large amplification, thus ensuring a rapid and amplified response to trauma. A similar mechanism is involved in the dissolution of blood clots, in which activation of plasminogen activators leads to conversion of plasminogen to plasmin, which is responsible for lysis of the fibrin clot. A third important example of the coordinated action of serine proteases involves the intestinal digestive enzymes. The digestion of proteins in the duodenum requires the concurrent action of several proteolytic enzymes. Coordinated control is achieved by the action of trypsin as the common activator of all pancreatic zymogens. The apoptosis pathway is another important example of coordinated action of proteases.

The cross-talk between kallikreins and the hypothesis that they are involved in a cascade enzymatic pathway are supported by strong, but mostly circumstantial, evidence, including the coexpression of many kallikreins in the same tissue and the ability of some kallikreins to activate each other (46–49). Added to this are the common patterns of hormonal regulation and the parallel pattern of differential expression of many kallikreins in diverse malignancies (Tables 3 and 4).

The interrelationships between some kallikreins are well documented. Recent experimental evidence has shown that hK3 (PSA) can be activated by hK15 (47). Prostase (hK4) has also recently been shown to activate hK3 much more efficiently compared with hK2 (48). hK5 is predicted to be able to activate hK7 in the skin (50). It will be interesting to study all possible combinations of interactions among kallikreins, especially those coexpressed in the same tissues. Bhoola et al. (51) have recently provided strong evidence of the involvement of a “kallikrein cascade” in initiating and maintaining systemic inflammatory responses and immune-modulated disorders.

Kallikreins might also be involved in cascade reactions involving other, nonkallikrein serine proteases. There is also a reported, but questionable, ability of hK3 to activate IGFBP-3 (52). hK3 can inactivate the N-terminal fragment of the parathyroid hormone-related protein (53). Experimental evidence has also shown that hK2 and hK4 can activate the proform of another serine protease, uPA (44, 50). The hypothetical involvement of a kallikrein cascade in the pathogenesis and progression of ovarian cancer is depicted in Fig. 2.

**Kallikreins as Cancer Biomarkers**

The genes encoding for PSA (hK3), hK2, and prostase (hK4) are tandemly localized and are highly expressed in the prostate. This restricted tissue expression and secretion of the proteases into biological fluids make them ideal markers for prostatic diseases. A more detailed discussion on hK2 and hK3 as cancer biomarkers can be found elsewhere (54). In addition to hK3 being an established marker for prostate cancer diagnosis and monitoring, recent reports suggest some usefulness of hK3 as a marker for breast cancer prognosis (42, 55, 56).

With the full identification and characterization of all members of the kallikrein gene family, accumulating reports started to indicate that other kallikreins might be also related to hormonal malignancies (for example,
breast, prostate, testicular, and ovarian cancers). KLK6 (zyme/protease M) was isolated by differential display from an ovarian cancer library (57), and KLK10 (NES1) was cloned by subtractive hybridization from a breast cancer library (58) and later shown to act as a tumor suppressor gene (59). Underwood et al. (60) and Magklara et al. (61) have shown that KLK8 (also known as neuropsin and TADG-14) is differentially expressed in ovarian cancer. KLK7 is up-regulated in ovarian cancer (62), and KLK4 and KLK5 are indicators of poor prognosis of ovarian cancer (63–65). More recently, KLK9 has been shown to be a marker of favorable prognosis for the same malignancy (66).

At the protein level, recent reports showed that kallikrein proteins can be useful serum biomarkers for the diagnosis and prognosis of cancer. In addition to hK3 and hK2, hK6 and hK10 are emerging diagnostic markers for ovarian cancer (67–70). More recently, hK11 was also shown to be a potential marker for ovarian and prostate cancer (71).

Added to the above evidence are the findings that all known kallikreins are under sex steroid hormone regulation in cancer cell lines (7, 13, 14, 22–24, 28, 72). Tables 3 and 4 summarize all the available data on measurement of kallikrein genes and proteins in serum and tumor tissue extracts for the purpose of disease diagnosis, monitoring, prognosis, or subclassification. It is clear from these data that at least a few kallikreins have already found important clinical applications, whereas other members show promising potential. The availability of sensitive analytical methods for the remaining kallikreins will allow their examination as candidate cancer biomarkers.

References


